These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16732153)

  • 1. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
    Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
    Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
    Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
    Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
    Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
    Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
    Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.
    Gatti G; Castelli-Gattinara G; Cruciani M; Bernardi S; De Pascalis CR; Pontali E; Papa L; Miletich F; Bassetti D
    Clin Infect Dis; 2003 Jun; 36(11):1476-82. PubMed ID: 12766843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.
    Larru B; de Mendoza C; Bellón JM; de José MI; Mellado MJ; Soriano V; Muñoz-Fernandez MA; Ramos JT
    BMC Infect Dis; 2007 Jun; 7():55. PubMed ID: 17559687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
    Hirt D; Urien S; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Treluyer JM
    Br J Clin Pharmacol; 2007 Nov; 64(5):634-44. PubMed ID: 17892516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
    Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
    Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
    Burger DM; Bergshoeff AS; De Groot R; Gibb D; Walker S; Tréluyer JM; Hoetelmans RM;
    J Pediatr; 2004 Sep; 145(3):403-5. PubMed ID: 15343199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
    J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose ritonavir moderately enhances nelfinavir exposure.
    Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
    Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
    Scherpbier HJ; Bekker V; van Leth F; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2006 Mar; 117(3):e528-36. PubMed ID: 16481448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM;
    Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
    Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
    Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
    Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.
    Grub S; Delora P; Lüdin E; Duff F; Fletcher CV; Brundage RC; Kline MW; Calles NR; Schwarzwald H; Jorga K
    Clin Pharmacol Ther; 2002 Mar; 71(3):122-30. PubMed ID: 11907486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.